Berger Montague PC Investigating Claims on Behalf of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) After Class Action Filing
Berger Montague PC Investigating Claims on Behalf of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) After Class Action Filing |
| [19-November-2025] |
PHILADELPHIA, Nov. 19, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix" or the "Company") on behalf of investors who purchased Telix securities during the period of February 21, 2025 through August 28, 2025 (the "Class Period"). Investor Deadline: Investors who purchased Telix securities during the Class Period may, no later than January 9, 2026, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE. The Company, based in Melbourne, Australia, focuses on radiopharmaceutical therapies and diagnostics for oncology. According to the allegations, throughout the Class Period, defendants misrepresented the Company's development progress, including overstating achievements in prostate cancer therapeutics and the reliability of its supply chain and partners. Consequently, statements about the Company's business, operations, and prospects were, according to the complaint, materially false or misleading and unsupported by a reasonable basis. When the truth about the Company's business was disclosed, investors suffered significant losses. If you are a Telix investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015, or Caitlin Adorni at cadorni@bergermontague.com or (267)764-4865. About Berger Montague For more information or to discuss your rights, please contact: Caitlin Adorni
SOURCE Berger Montague | ||
Company Codes: NASDAQ-NMS:TLX |













